Skip to main content

Table 2 PET-CT indices and EC risk stratification

From: Risk stratification of endometrial cancer and lymph node metastases prediction using 18F-FDG PET/CT: role of metabolic tumor volume and total lesion glycolysis

Parameter Cases (%) SUVmax SUVmean MTV TLG
Histopathological grade
G 1 15 (45.5%) 14.64 ± 4.26 7.39 ± 1.97 21.09 ± 9.57 166.97 ± 105.75
G 2&3 18 (54.5%) 19.19 ± 7.3 9.06 ± 3.34 37.53 ± 16.51 348.05 ± 222.83
P-value   0.0414 0.0986 0.0019 0.0071
95% CI   0.188 to 8.912  − 0.33 to 3.67 6.59 to 26.29 52.975 to 309.185
Myometrial invasion
 < 50% 15 (45.5%) 12.75 ± 2.23 6.52 ± 1.71 19.95 ± 9.86 132.86 ± 84.91
 > 50% 18 (54.5%) 20.77 ± 6.67 9.79 ± 2.89 38.49 ± 15.32 376.48 ± 202.22
P-value   0.0001 0.0006 0.0003 0.0001
95% CI   4.34 to 11.7 1.538 to 5.002 9.172 to 27.908 129.356 to 357.884
LVSI
Negative 15 (45.5%) 14.06 ± 4.28 6.65 ± 1.88 20.64 ± 8.94 139.63 ± 82.05
Positive 18 (54.5%) 19.68 ± 6.95 9.68 ± 2.92 37.91 ± 16.42 370.83 ± 209.69
P-value   0.0104 0.0016 0.0010 0.0004
95% CI   1.416 to 9.824 1.244 to 4.816 7.599 to 26.941 113.708 to 348.692
LNMs
Negative 24 (72.7%) 14.8 ± 4.33 7.22 ± 2.09 24.47 ± 12.37 176.26 ± 97.99
Positive 9 (27.3%) 23.32 ± 7.27 11.19 ± 2.87 44.98 ± 15.15 504.36 ± 209.42
P-value   0.0002 0.0001 0.0004  < 0.0001
95% CI   4.336 to 12.704 2.123 to 5.817 10.032 to 30.988 219.842 to 436.358
Risk stratification
LR 11 (33.3%) 12.76 ± 2.07 6.61 ± 1.54 18.72 ± 9.46 132.06 ± 91.49
HR 22 (66.7%) 19.3 ± 6.88 9.15 ± 3.08 35.73 ± 15.65 332.58 ± 207.02
P-value   0.0045 0.0154 0.0024 0.0047
95% CI   2.184 to 10.896 0.52 to 4.56 6.499 to 27.521 66.358 to 334.682
  1. LVSI, Lymphovascular space invasion, LNMs, Lymph nodes metastases, LR, Low Risk, HR, High Risk